ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Entry into a Material Definitive Agreement

ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

An ad to help with our costs